The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions
Official Title: Identification of Key Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais, Normandy and Picardy Regions
Study ID: NCT02121730
Brief Summary: Kidney transplantation is now the treatment of choice for end-stage renal disease (ESRD). Between 2800 and 3000 kidney transplants are performed each year in France and more than 33 000 patients are living with a functioning graft. Preventing allograft rejection requires the use of immunosuppressive therapy, the intensity decreases as the distance from the day of transplantation. Unfortunately, treatment favors certain complications, including infectious and neoplastic. These represent a major cause of mortality in these patients. If the frequency of skin cancer is greatly increased in this population, that of solid tumors remains a concern. Approximately 20% of patients develop cancer after 10 years of graft , half non- skin cancers, the main risk factor is immunosuppressive therapy . The aim of the study is to evaluate, in a large population of patients treated in 4 regions ( the Nord-Pas de Calais, the Upper and Lower Normandy and Picardy) risk factors (in particular the nature of the immunosuppressive treatment) of developing a neoplastic complication, skin cancers and solid tumors, after renal transplantation.
Detailed Description: A retrospective analysis of the previous 10 years, from 2002 to 2011 will be conducted. This study will better understand the epidemiology of these complications but also allow to identify risk factors associated, including demographic, environmental and related to immunosuppressive therapy. Thereafter, we hope to implement preventive measures or prospective studies, allowing us to reduce the prevalence of this complication.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
CHU Amiens, Amiens, , France
CHU CAEN, Caen, , France
Chru Lille, Lille, , France
Chu Rouen, Rouen, , France
Name: Gabriel Choukroun, MD, PhD
Affiliation: CHU Amiens
Role: STUDY_DIRECTOR
Name: Marc Hazzan, MD, PhD
Affiliation: CHRU Lille
Role: STUDY_CHAIR
Name: Bruno Hurault de Ligny, MD, PhD
Affiliation: CHU Caen
Role: STUDY_CHAIR
Name: Michel Godin, MD, PhD
Affiliation: CHU Rouen
Role: STUDY_CHAIR